HITIQ Limited has drawn down a $1 million loan from a major shareholder associate, with plans to convert the debt into convertible notes subject to shareholder approval. The initial tranche aims to bolster working capital amid ongoing capital market challenges.
- Received $1 million loan from associate of substantial shareholder
- Initial $250,000 advanced for immediate working capital needs
- Loan carries 12.5% interest with planned conversion to convertible notes
- Convertible notes terms mirror those issued in January 2026
- Extraordinary general meeting to seek shareholder approval forthcoming
Loan Injection Targets Working Capital Pressure
HITIQ Limited (ASX:HIQ) has tapped a $1 million loan from No Bull Health, linked to Harmil Angel Investments, one of its substantial shareholders. The company has already accessed $250,000 of this facility to ease near-term working capital constraints. This move comes as HITIQ navigates a tough capital environment, with Executive Chair Earl Eddings describing the funding as a prudent step within their broader capital management strategy.
Convertible Notes to Replace Loan Pending Approvals
The loan bears a hefty 12.5% annual interest rate and is structured with an eye towards conversion into convertible notes, subject to shareholder and regulatory approvals. These notes are expected to closely replicate the terms of those issued to Harmil in January 2026, which were detailed in the company’s Notice of General Meeting released on 8 January 2026. Until approvals are secured, the loan remains unsecured but will be backed by a general security deed over company assets once converted.
HITIQ plans to hold an extraordinary general meeting in the coming months to formalise this arrangement. The final terms and security details will be disclosed in the meeting notice. This funding approach follows the company’s recent capital raising efforts, including a $1.4 million raise earlier this year amid a $2.9 million half-year loss, underscoring the ongoing need to support its transition from technology validation to commercial execution capital raising efforts.
Strategic Implications for HITIQ’s Growth Trajectory
HITIQ’s core technology, PROTEQT™, a concussion management solution co-developed with Shock Doctor, remains central to its growth ambitions. The company has been expanding its footprint globally, securing deals such as a three-year partnership with Hockey Australia and entry into North American markets. However, the reliance on shareholder-linked funding highlights the challenges HITIQ faces in balancing growth and financial sustainability.
The loan and proposed convertible notes issuance represent a tactical move to maintain operational momentum without immediate equity dilution, though eventual conversion will impact capital structure. Investors will be watching closely for the outcomes of the upcoming shareholder meeting and the precise terms of the convertible notes, which will clarify the degree of dilution and debt servicing obligations.
Bottom Line?
HITIQ’s latest funding underscores its delicate balancing act between sustaining operations and managing shareholder dilution amid challenging capital markets.
Questions in the middle?
- Will shareholder approval for the convertible notes proceed smoothly given the terms and existing shareholder interests?
- How will the conversion of this loan into notes affect HITIQ’s capital structure and investor sentiment?
- Can HITIQ leverage this funding to accelerate commercialisation of PROTEQT™ amid ongoing losses?